pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The September 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:
- Six new drug products have initiated pCPA negotiations, for a total of 51 active negotiations;
- Two negotiations have been completed/closed, for a total of 170 joint completed/closed negotiations; and
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 55 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since August 31, 2017 is:
- Two new drug products have received recent CDEC or pERC recommendations, for a total of approximately 18 products under pCPA Consideration
Please see below for more details.
- Six new drug products have initiated pCPA negotiations since the last update, for a total of 51 active negotiations
Brand Name |
Generic Name |
Manufacturer |
Indication |
Recommendation/Notification to Implement Date |
Time to Negotiation*
|
|---|---|---|---|---|---|
Fibristal |
ulipristal acetate | Actavis Speciality Pharmaceuticals Co. | Uterine fibroids (2nd cycle pre-surgery) | Not yet complete | N/A |
Glatect |
Glatiramer acetate | Pendopharm | Relapsing remitting multiple sclerosis | July 25, 2017 | 52 |
Keytruda |
Pembrolizumab | Merck Canada Inc. | Non-small cell lung cancer (first line) | September 8, 2017 | 7 |
Kyleena |
Levonorgestrel | Bayer | Prevention of pregnancy | N/A | N/A |
Opdivo |
nivolumab | Bristol-Myers Squibb Canada | Squamous cell carcinoma of the head and neck (SCCHN) | September 18, 2017 | 0 |
Tagrisso |
osimertinib | AstraZeneca Canada Inc. | Locally advanced or metastatic EGFR T790M mutation positive non-small lung cancer who have progressed on or after EGFR TKI therapy | May 19, 2017 | 119 |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
- Two negotiations have been completed/closed since the last update, for a total of 170 joint completed/closed negotiations.
- Two negotiations were closed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration *
|
|---|---|---|---|---|---|
| Campral | Acamprosate calcium | Prempharm Inc. | Alcohol Abstinence | March, 2017 | 184 |
| Otezla | Apremilast | Celgene | Moderate to severe plaque psoriasis | June, 2017 | 92 |
*Approximation: Negotiation initiation and end date assumed to be mid-month for the purposes of the calculation
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 55 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
- Truvada (emtricitabine/tenofovir disoproxil fumarate) Gilead Science Inc. – pre-exposure prophylaxis of HIV-1 infection
Based on information collected by MORSE Consulting:
- One new drug product received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 17 products under pCPA Consideration.
Please note; the date provided is the date of the Final Recommendation or Notification to Implement where applicable. - Lynparza (olaparib; AstraZeneca Canada Inc.; October 5, 2017) – ovarian cancer Resubmission
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
